176 related articles for article (PubMed ID: 20546333)
1. Genomic and immunophenotypical differences between hepatocellular carcinoma with and without cirrhosis.
Tretiakova MS; Shabani-Rad MT; Guggisberg K; Hart J; Anders RA; Gao ZH
Histopathology; 2010 May; 56(6):683-93. PubMed ID: 20546333
[TBL] [Abstract][Full Text] [Related]
2. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis.
Qin LF; Ng IO
Hum Pathol; 2001 Aug; 32(8):778-84. PubMed ID: 11521219
[TBL] [Abstract][Full Text] [Related]
3. Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas.
Shi YZ; Hui AM; Takayama T; Li X; Cui X; Makuuchi M
Br J Cancer; 2000 Jul; 83(1):50-5. PubMed ID: 10883667
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
[TBL] [Abstract][Full Text] [Related]
5. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
[TBL] [Abstract][Full Text] [Related]
6. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
Lou C; Yang B; Gao YT; Wang YJ; Nie FH; Yuan Q; Zhang CL; Du Z
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):831-6. PubMed ID: 19173828
[TBL] [Abstract][Full Text] [Related]
7. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma.
Naka T; Toyota N; Kaneko T; Kaibara N
Anticancer Res; 1998; 18(1B):555-64. PubMed ID: 9568177
[TBL] [Abstract][Full Text] [Related]
8. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
9. [Determination of expression of eight p53-related genes in hepatocellular carcinoma with tissue microarrays].
Zhu MH; Ni CR; Zhu Z; Li FM; Zhang SM
Ai Zheng; 2003 Jul; 22(7):680-5. PubMed ID: 12866955
[TBL] [Abstract][Full Text] [Related]
10. [WAF1/CIP1 gene expression in human hepatocellular carcinoma and its relationship with p53 mutation].
Zhu B; Cong W; Wang H
Zhonghua Gan Zang Bing Za Zhi; 1999 Dec; 7(4):217-20. PubMed ID: 10715791
[TBL] [Abstract][Full Text] [Related]
11. Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma.
Lee TK; Man K; Poon RT; Lo CM; Ng IO; Fan ST
Oncol Rep; 2004 Jul; 12(1):25-31. PubMed ID: 15201954
[TBL] [Abstract][Full Text] [Related]
12. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
[TBL] [Abstract][Full Text] [Related]
13. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma.
Roncalli M; Bianchi P; Bruni B; Laghi L; Destro A; Di Gioia S; Gennari L; Tommasini M; Malesci A; Coggi G
Hepatology; 2002 Aug; 36(2):427-32. PubMed ID: 12143052
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer.
Bali A; O'Brien PM; Edwards LS; Sutherland RL; Hacker NF; Henshall SM
Clin Cancer Res; 2004 Aug; 10(15):5168-77. PubMed ID: 15297421
[TBL] [Abstract][Full Text] [Related]
15. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection.
Kao JT; Chuah SK; Huang CC; Chen CL; Wang CC; Hung CH; Chen CH; Wang JH; Lu SN; Lee CM; Changchien CS; Hu TH
Liver Int; 2007 Aug; 27(6):772-81. PubMed ID: 17617120
[TBL] [Abstract][Full Text] [Related]
16. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis.
Mao TL; Chu JS; Jeng YM; Lai PL; Hsu HC
J Pathol; 2001 Jan; 193(1):95-101. PubMed ID: 11169521
[TBL] [Abstract][Full Text] [Related]
17. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance.
Claudio PP; Russo G; Kumar CA; Minimo C; Farina A; Tutton S; Nuzzo G; Giuliante F; Angeloni G; Maria V; Vecchio FM; Campli CD; Giordano A
Clin Cancer Res; 2004 May; 10(10):3509-17. PubMed ID: 15161709
[TBL] [Abstract][Full Text] [Related]
18. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
Xue KX
Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
[TBL] [Abstract][Full Text] [Related]
20. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
